NASDAQ:INBX

Inhibrx Competitors

$18.03

-2.95 (-14.06 %)

(As of 04/16/2021 04:00 PM ET)

Add

Compare

Today's Range

$17.91

Now: $18.03▼

$20.90

50-Day Range

$16.27

MA: $22.47▼

$29.75

52-Week Range

$15.20

Now: $18.03▼

$50.97

Volume128,524 shs

Average Volume147,164 shs

Market Capitalization$680.60 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Inhibrx (NASDAQ:INBX) Vs. VCEL, EDIT, SRNE, BCRX, RUBY, and BLUE

Should you be buying INBX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Inhibrx, including Vericel (VCEL), Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), BioCryst Pharmaceuticals (BCRX), Rubius Therapeutics (RUBY), and bluebird bio (BLUE).

Inhibrx vs. Vericel Stock

Vericel (NASDAQ:VCEL) and Inhibrx (NASDAQ:INBX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Earnings and Valuation

This table compares Vericel and Inhibrx's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$117.85 million	22.93	$-9,660,000.00	$0.18	325.67
Inhibrx	N/A	N/A	N/A	N/A	N/A

Inhibrx has lower revenue, but higher earnings than Vericel.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vericel and Inhibrx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0	2	6	0	2.75
Inhibrx	0	0	4	0	3.00

Vericel currently has a consensus target price of $49.00, suggesting a potential downside of 16.41%. Inhibrx has a consensus target price of $34.6667, suggesting a potential upside of 92.27%. Given Inhibrx's stronger consensus rating and higher possible upside, analysts plainly believe Inhibrx is more favorable than Vericel.

Insider and Institutional Ownership

93.1% of Vericel shares are owned by institutional investors. Comparatively, 36.6% of Inhibrx shares are owned by institutional investors. 4.3% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Vericel and Inhibrx's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vericel	0.12%	0.13%	0.10%
Inhibrx	N/A	N/A	N/A

Summary

Vericel beats Inhibrx on 7 of the 9 factors compared between the two stocks.

Inhibrx vs. Editas Medicine Stock

Inhibrx (NASDAQ:INBX) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares Inhibrx and Editas Medicine's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx	N/A	N/A	N/A	N/A	N/A
Editas Medicine	$20.53 million	113.76	$-133,750,000.00	($2.68)	-12.94

Inhibrx has higher earnings, but lower revenue than Editas Medicine.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Inhibrx and Editas Medicine, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx	0	0	4	0	3.00
Editas Medicine	4	4	4	0	2.00

Inhibrx presently has a consensus price target of $34.6667, suggesting a potential upside of 92.27%. Editas Medicine has a consensus price target of $47.3636, suggesting a potential upside of 36.61%. Given Inhibrx's stronger consensus rating and higher possible upside, research analysts clearly believe Inhibrx is more favorable than Editas Medicine.

Insider and Institutional Ownership

36.6% of Inhibrx shares are owned by institutional investors. Comparatively, 87.5% of Editas Medicine shares are owned by institutional investors. 0.9% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Inhibrx and Editas Medicine's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibrx	N/A	N/A	N/A
Editas Medicine	-99.62%	-26.74%	-16.38%

Summary

Inhibrx beats Editas Medicine on 5 of the 8 factors compared between the two stocks.

Inhibrx vs. Sorrento Therapeutics Stock

Inhibrx (NASDAQ:INBX) and Sorrento Therapeutics (NASDAQ:SRNE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares Inhibrx and Sorrento Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx	N/A	N/A	N/A	N/A	N/A
Sorrento Therapeutics	$31.43 million	66.93	$-292,070,000.00	($2.12)	-3.53

Inhibrx has higher earnings, but lower revenue than Sorrento Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Inhibrx and Sorrento Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx	0	0	4	0	3.00
Sorrento Therapeutics	0	0	4	0	3.00

Inhibrx presently has a consensus price target of $34.6667, suggesting a potential upside of 92.27%. Sorrento Therapeutics has a consensus price target of $28.75, suggesting a potential upside of 283.85%. Given Sorrento Therapeutics' higher possible upside, analysts clearly believe Sorrento Therapeutics is more favorable than Inhibrx.

Insider and Institutional Ownership

36.6% of Inhibrx shares are owned by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are owned by institutional investors. 3.4% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Inhibrx and Sorrento Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibrx	N/A	N/A	N/A
Sorrento Therapeutics	-698.01%	-314.06%	-43.60%

Summary

Inhibrx beats Sorrento Therapeutics on 4 of the 7 factors compared between the two stocks.

Inhibrx vs. BioCryst Pharmaceuticals Stock

Inhibrx (NASDAQ:INBX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares Inhibrx and BioCryst Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx	N/A	N/A	N/A	N/A	N/A
BioCryst Pharmaceuticals	$48.83 million	40.86	$-108,900,000.00	($0.94)	-11.96

Inhibrx has higher earnings, but lower revenue than BioCryst Pharmaceuticals.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Inhibrx and BioCryst Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx	0	0	4	0	3.00
BioCryst Pharmaceuticals	0	3	8	0	2.73

Inhibrx presently has a consensus price target of $34.6667, suggesting a potential upside of 92.27%. BioCryst Pharmaceuticals has a consensus price target of $12.3333, suggesting a potential upside of 9.73%. Given Inhibrx's stronger consensus rating and higher possible upside, research analysts clearly believe Inhibrx is more favorable than BioCryst Pharmaceuticals.

Insider and Institutional Ownership

36.6% of Inhibrx shares are owned by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Inhibrx and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibrx	N/A	N/A	N/A
BioCryst Pharmaceuticals	-233.45%	-328.70%	-71.11%

Summary

Inhibrx beats BioCryst Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Inhibrx vs. Rubius Therapeutics Stock

Inhibrx (NASDAQ:INBX) and Rubius Therapeutics (NASDAQ:RUBY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Insider and Institutional Ownership

36.6% of Inhibrx shares are owned by institutional investors. Comparatively, 93.7% of Rubius Therapeutics shares are owned by institutional investors. 58.4% of Rubius Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Inhibrx and Rubius Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibrx	N/A	N/A	N/A
Rubius Therapeutics	N/A	-77.33%	-49.05%

Valuation & Earnings

This table compares Inhibrx and Rubius Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx	N/A	N/A	N/A	N/A	N/A
Rubius Therapeutics	N/A	N/A	$-163,460,000.00	($2.08)	-11.68

Analyst Ratings

This is a breakdown of recent ratings and price targets for Inhibrx and Rubius Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx	0	0	4	0	3.00
Rubius Therapeutics	0	3	1	0	2.25

Inhibrx presently has a consensus price target of $34.6667, suggesting a potential upside of 92.27%. Rubius Therapeutics has a consensus price target of $23.3333, suggesting a potential downside of 2.17%. Given Inhibrx's stronger consensus rating and higher possible upside, research analysts clearly believe Inhibrx is more favorable than Rubius Therapeutics.

Summary

Inhibrx beats Rubius Therapeutics on 5 of the 7 factors compared between the two stocks.

Inhibrx vs. bluebird bio Stock

Inhibrx (NASDAQ:INBX) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

36.6% of Inhibrx shares are held by institutional investors. Comparatively, 94.3% of bluebird bio shares are held by institutional investors. 3.6% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Inhibrx and bluebird bio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibrx	N/A	N/A	N/A
bluebird bio	-256.84%	-45.78%	-35.14%

Earnings and Valuation

This table compares Inhibrx and bluebird bio's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx	N/A	N/A	N/A	N/A	N/A
bluebird bio	$44.67 million	42.51	$-789,610,000.00	($14.31)	-1.98

Inhibrx has higher earnings, but lower revenue than bluebird bio.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Inhibrx and bluebird bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx	0	0	4	0	3.00
bluebird bio	0	12	6	0	2.33

Inhibrx presently has a consensus price target of $34.6667, suggesting a potential upside of 92.27%. bluebird bio has a consensus price target of $61.40, suggesting a potential upside of 112.16%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Inhibrx.

Summary

bluebird bio beats Inhibrx on 5 of the 9 factors compared between the two stocks.